FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
FDA Grants Fast Track Designation to BGB-16673
FDA Approves Lazertinib With Amivantamab-vmjw for Non-Small Cell Lung Cancer
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable Non-Small Cell Lung Cancer
FDA Approves Axatilimab-csfr for Chronic Graft-Versus-Host Disease
FDA Approves Daratumumab and Hyaluronidase-fihj for Select Patients with Multiple Myeloma
Updated NCCN Guidelines Recommend Imetelstat for Symptomatic Anemia in Select Patients
FDA Approves Repotrectinib for Patients with NTRK Gene Fusion-Positive Solid Tumors
FDA Grants Approves Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
FDA Approves Adagrasib + Cetuximab for KRAS G12C-Mutated Colorectal Cancer
FDA Approves Durvalumab + Chemotherapy for Endometrial Cancer
FDA Approves Pembrolizumab + Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma
FDA Approves Selpercatinib for RET Fusion-Positive Thyroid Cancer
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approves Lisocabtagene Maraleucel for Follicular Lymphoma
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
FDA Approves Lutetium Lu 177 Dotatate for Pediatric Patients with Astroenteropancreatic Neuroendocrine Tumors
FDA Approves Nogapendekin Alfa Inbakicept-pmln for Invasive Bladder Cancer
FDA Approves Alectinib for ALK-positive Non-Small Cell Lung Cancer
FDA Approves Fam-trastuzumab deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumors
FDA Approves Mirvetuximab Soravtansine-gynx for Certain Ovarian Cancers
FDA Approves Safety Labeling Changes for Fluorouracil Injection Products
FDA Approves Oral Suspension Ibrutinib in Adults with Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
FDA Approves Ponatinib + Chemotherapy for Lymphoblastic Leukemia
FDA Approves Tislelizumabjsgr for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Changes to Ropeginterferon alfa-2b-njft in Updated NCCN Clinical Practice Guidelines
FDA Approves Zanubrutinib for Relapsed or Refractory Follicular Lymphoma
FDA Approves Nivolumab + Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients with Acute Lymphoblastic Leukemia
FDA Approves Amivantamab-vmjw for Non-small Cell Lung Cancer
